The present invention provides an MPHOSPH1-derived epitope peptide exhibiting cytotoxic T lymphocyte inducibility. The present invention also provides: a polynucleotide encoding said peptide； an antigen-presenting cell presenting said peptide； a cytotoxic T lymphocyte (CTL) targeting said peptide； and a method for inducing the antigen-presenting cell or the CTL. Furthermore, the present invention provides a composition and a pharmaceutical composition which include the peptide, the polynucleotide, the antigen-presenting cell, and the CTL as active ingredients. Moreover, the present invention provides a method which uses the peptide, the polynucleotide, the antigen-presenting cell, the CTL, or the pharmaceutical composition to treat and/or prevent cancer, and/or prevent the postoperative recurrence of cancer. Also provided is a method for inducing an immune response against cancer.
